Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
For small cell lung carcinoma, the sensitivity of INSM1 (98%) was similar to synaptophysin (100%) and CD56 (95%) but considerably higher than chromogranin (83%).
|
30154579 |
2019 |
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared diagnostic performance of INSM1 and previously reported composite marker CD56 + p16 + thyroid transcription factor-1 (TTF1) in the diagnosis of SCLC in small biopsy specimens and cytoblocks.
|
30385371 |
2019 |
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (ASCL1, BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (NF1B).
|
29787820 |
2018 |
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, Promiximab-MMAE is a potential candidate for the treatment of CD56 positive small cell lung cancer.
|
29630426 |
2018 |
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CD56 antigen (NCAM-1) is highly expressed on several malignancies with neuronal or neuroendocrine differentiation, including small-cell lung cancer and neuroblastoma, tumor types for which new therapeutic options are needed.
|
29622795 |
2018 |
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of CD56, p16 and TTF1 produced diagnostic classifier that outperformed best single marker CD56 in differential diagnosis between SCLC and NSCLC.
|
29566943 |
2018 |
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD56, a cell surface marker highly expressed on most SCLC, is a promising therapeutic target for treatment of this aggressive cancer.
|
29435172 |
2018 |
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
On Immunohistochemistry, presence of chromogranin, synaptophysin, and CD-56 is necessary to make a diagnosis of small cell carcinoma.
|
29937242 |
2018 |
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).
|
28349943 |
2017 |
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
|
28341109 |
2017 |
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of the INSM1 gene in adenocarcinoma cell lines (H358 and H1975) induced the expression of ASCL1, brain-2 (BRN2), chromogranin A, synaptophysin, and neural cell adhesion molecule 1; in contrast, knockdown of the INSM1 gene by siRNA in SCLC (H69 and H889) decreased their expression.
|
26482608 |
2015 |
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the importance of BRN2 in the expression of the lineage-specific transcription factors (achaete-scute homolog-like 1 (ASCL1) and NeuroD1 (ND1)) and neural/neuroendocrine marker molecules (neural cell adhesion molecule 1 (NCAM1), synaptophysin (SYP) and chromogranin A (CHGA)) in small cell lung cancer (SCLC) using cultured lung cancer cells.
|
23530560 |
2013 |
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In two areas of SCLC distinguishable by divergent neuroendocrine marker expression (CD56 and chromogranin-A), the presence of identical genomic breakpoints and rearrangements indicated a common origin, with the presence of additional distinct genomic alterations in these two components indicating diverging clonal evolution.
|
19179901 |
2009 |
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prevalent expression of synaptophysin and CD56 and loss of 22q13 suggest that these tumors are biologically closer to SCLC.
|
19228643 |
2009 |
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CEA, TPA, SCC-Ag, CYFRA 21-1, ferritin, CA19-9, CA50, CA242, H-K-N-ras mutations and p53 mutation seem to be the most prolific in NSCLC, while NSE, BN/GRP, CK-BB, NCAM, IL-2R, IGF-I, transferrin, ANP, mAb (cluster 5), Le-y and c-N-L-myc mutation are markers in SCLC patients.
|
7539317 |
1995 |